$18.92
0.64% today
Nasdaq, Feb 05, 04:08 pm CET
ISIN
US8162121045
Symbol
RNAC
Sector
Industry

Cartesian Therapeutics Stock price

$18.80
+1.17 6.64% 1M
+4.82 34.48% 6M
+0.89 4.97% YTD
-0.48 2.51% 1Y
-15.10 44.54% 3Y
-35.95 65.66% 5Y
-191.20 91.05% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-1.09 5.48%
ISIN
US8162121045
Symbol
RNAC
Sector
Industry

Key metrics

Market capitalization $483.64m
Enterprise Value $279.09m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.82
P/S ratio (TTM) P/S ratio 10.09
P/B ratio (TTM) P/B ratio 597.39
Revenue growth (TTM) Revenue growth 38.82%
Revenue (TTM) Revenue $47.94m
EBIT (operating result TTM) EBIT $-52.71m
Free Cash Flow (TTM) Free Cash Flow $-48.41m
Cash position $219.20m
EPS (TTM) EPS $-52.64
P/E forward negative
P/S forward 12.17
EV/Sales forward 7.02
Short interest 13.35%
Show more

Is Cartesian Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Cartesian Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Cartesian Therapeutics forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Cartesian Therapeutics forecast:

Buy
75%
Hold
25%

Financial data from Cartesian Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
48 48
39% 39%
100%
- Direct Costs 0.94 0.94
54% 54%
2%
47 47
45% 45%
98%
- Selling and Administrative Expenses 43 43
107% 107%
89%
- Research and Development Expense 56 56
18% 18%
117%
-52 -52
8% 8%
-108%
- Depreciation and Amortization 0.94 0.94
54% 54%
2%
EBIT (Operating Income) EBIT -53 -53
10% 10%
-110%
Net Profit -287 -287
693% 693%
-598%

In millions USD.

Don't miss a Thing! We will send you all news about Cartesian Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cartesian Therapeutics Stock News

Neutral
GlobeNewsWire
9 days ago
FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the overall design of the Company'...
Neutral
GlobeNewsWire
29 days ago
FREDERICK, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to three new employees. On January 2, 2025, the Company issued to these employees options to purchase an aggregate of 19,324...
Neutral
GlobeNewsWire
about 2 months ago
FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On December 12, 2024, the Company issued to these employees options to purchase an aggregate of 25,60...
More Cartesian Therapeutics News

Company Profile

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Head office United States
CEO Carsten Brunn
Employees 38
Founded 2007
Website www.cartesiantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today